Ann: Trading Halt, page-233

I take your point @angelus512.

For clarity though, I wasn't suggesting that if the FDA outright rejects this then everything is fine and we'll just move on.

In that scenario, what we don't know are the reasons for any potential theoretical rejection might be yet, and what bearing that may (or may not) have on other work being done by MSB. Just as we don't know what the conditions would be for a potential theoretical conditional approval.

There are too many unknowns for firm conclusions to be drawn at this stage. That's all I was suggesting.

I know it's comforting to try and see this in black and white. But, as much as we'd like it to be for our investment case, there are too many unknown variables here at the moment.

We'll have that clarity within the next few days.

Just my opinion.